In the largest comparison of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors to date, a study of nearly 2.3 million patients starting the drugs as monotherapy ...

In more than 3 million people worldwide treated for hypertension, ARBs were not only just as effective as ACE inhibitors at reducing the risk of major cardiovascular events, but also associated with a ...

Close-up of senior black woman sorting weekly medication. Member of a black middle class America family. Currently, ACE inhibitors and ARBs are both recommended as first-line therapies for the ...

The new data, published this week in JAMA Network Open, show that after adjusting for multiple variables, COVID-19 patients treated with ACE inhibitors and ARBs had a significantly lower risk of death ...

Angiotensin-converting–enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) are recommended widely as first-line treatments for hypertension in patients with diabetic or nondiabetic ...

Since the introduction of ARBs, the question that has pervaded each clinician’s mind is whether or not these drugs serve an advantage in conditions long addressed by ACE inhibitors. Matchar et al ...

Please provide your email address to receive an email when new articles are posted on . Angiotensin receptor blockers don’t significantly differ compared with ACE inhibitors as first-line treatment ...

Real-world EHR data suggest ACE inhibitor use is independently associated with lower all-cause mortality in idiopathic pulmonary fibrosis, while no similar survival association was observed in COPD.

Angiotensin converting enzyme (ACE) inhibitors, a type of blood pressure medication, are usually well tolerated, but one of their rare side effects is angioedema. Angiotensin converting enzyme (ACE) ...